Exelixis (NASDAQ:EXEL) shares, with a market capitalization of $9.2 billion, received an optimistic update from Morgan Stanley (NYSE:MS), as the firm's analyst Sean Laaman upgraded the biopharmaceutical company's stock rating from Equalweight to Overweight.

Morgan Stanley downgraded Intellia Therapeutics (NTLA) to Equal Weight from Overweight with a price target of $11, down from $56. The firm now

Morgan Stanley has downgraded Intellia Therapeutics (NASDAQ:NTLA) to equal weight from overweight citing "a more measured launch" of its transthyretin amyloidosis (ATTR) candidate nexiguran ziclumeran.

Morgan Stanley (NYSE:MS) reaffirmed its Overweight rating and $430.00 price target for Tesla stock (NASDAQ:TSLA), highlighting the company's potential in the growing field of embodied artificial intelligence (AI).